Global drug discovery and development services company, Crown Bioscience, has been selected as a strategic partner by Phanes Therapeutics to accelerate the discovery and development of novel oncology agents.
Acquisition puzzle
Under the terms of the agreement, Phanes will have access to CrownBio’s clinically relevant CDX models, exclusive patient-derived xenograft (PDX) models and in vitro assays in order to advance its oncology drug discovery pipeline.
“We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules,” explained Dr Ming Wang, president and CEO of Phanes Therapeutics. “We are very glad to partner with CrownBio. They have very unique MuPrime models, as well as Humanized GEMMs (HuGEMM) and PDX models for our oncology programs. We look forward to a productive partnership.”
“We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds,” added Laurie Heilmann, CrownBio's chief business officer. “Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer.”